Long-term independence and quality of life after subthalamic stimulation in Parkinson disease.


Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
09 2022
Historique:
revised: 19 05 2022
received: 18 03 2022
accepted: 30 05 2022
pubmed: 7 6 2022
medline: 9 8 2022
entrez: 6 6 2022
Statut: ppublish

Résumé

Studies on long-term nonmotor outcomes of subthalamic nucleus stimulation in Parkinson disease (PD) are scarce. This study reports on very long-term non-motor and motor outcomes in one of the largest cohorts of people with advanced PD, treated for >10 years with subthalamic nucleus stimulation. The main outcome was to document the evolution of independence in activities of daily living. The secondary outcomes were to measure the change in quality of life, as well as non-motor and motor outcomes. Patients were studied preoperatively, at 1 year, and beyond 10 years after subthalamic stimulation with an established protocol including motor, non-motor, and neuropsychological assessments. Eighty-five people with PD were included. Independence scores in the off-medication condition (measured with the Schwab & England Activities of Daily Living Scale) as well as quality of life (measured with the Parkinson's Disease Questionnaire [PDQ]-37) remained improved at longest follow-up compared to preoperatively (respectively, p < 0.001, p = 0.015). Cognitive scores, measured with the Mattis Dementia Rating Scale, significantly worsened compared to before and 1 year after surgery (p < 0.001), without significant change in depression, measured with the Beck Depression Inventory. Motor fluctuations, dyskinesias, and off dystonia remained improved at longest follow-up (p < 0.001), with a significant reduction in dopaminergic treatment (45%, p < 0.001). This study highlights the long-term improvement of subthalamic stimulation on independence and quality of life, despite the progression of disease and the occurrence of levodopa-resistant symptoms.

Sections du résumé

BACKGROUND AND PURPOSE
Studies on long-term nonmotor outcomes of subthalamic nucleus stimulation in Parkinson disease (PD) are scarce. This study reports on very long-term non-motor and motor outcomes in one of the largest cohorts of people with advanced PD, treated for >10 years with subthalamic nucleus stimulation. The main outcome was to document the evolution of independence in activities of daily living. The secondary outcomes were to measure the change in quality of life, as well as non-motor and motor outcomes.
METHODS
Patients were studied preoperatively, at 1 year, and beyond 10 years after subthalamic stimulation with an established protocol including motor, non-motor, and neuropsychological assessments.
RESULTS
Eighty-five people with PD were included. Independence scores in the off-medication condition (measured with the Schwab & England Activities of Daily Living Scale) as well as quality of life (measured with the Parkinson's Disease Questionnaire [PDQ]-37) remained improved at longest follow-up compared to preoperatively (respectively, p < 0.001, p = 0.015). Cognitive scores, measured with the Mattis Dementia Rating Scale, significantly worsened compared to before and 1 year after surgery (p < 0.001), without significant change in depression, measured with the Beck Depression Inventory. Motor fluctuations, dyskinesias, and off dystonia remained improved at longest follow-up (p < 0.001), with a significant reduction in dopaminergic treatment (45%, p < 0.001).
CONCLUSIONS
This study highlights the long-term improvement of subthalamic stimulation on independence and quality of life, despite the progression of disease and the occurrence of levodopa-resistant symptoms.

Identifiants

pubmed: 35666167
doi: 10.1111/ene.15436
pmc: PMC9543065
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2645-2653

Informations de copyright

© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Références

Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Neurology. 2021 Jun 2;:
pubmed: 34078713
Int J Environ Res Public Health. 2020 Dec 29;18(1):
pubmed: 33383855
Mov Disord. 1997 Nov;12(6):916-22
pubmed: 9399215
J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):251-7
pubmed: 22180646
J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1419-25
pubmed: 24790212
J Med Ethics. 2021 Jan;47(1):20-25
pubmed: 32409626
Mov Disord. 2021 Jan;36(1):106-117
pubmed: 33002231
Neurol India. 2016 Jan-Feb;64(1):81-9
pubmed: 26754997
NPJ Parkinsons Dis. 2021 Jun 8;7(1):48
pubmed: 34103534
N Engl J Med. 2003 Nov 13;349(20):1925-34
pubmed: 14614167
Eur J Neurol. 2016 Jan;23(1):53-61
pubmed: 25492023
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Arch Neurol. 2005 Aug;62(8):1250-5
pubmed: 15956104
Eur J Neurol. 2022 Sep;29(9):2645-2653
pubmed: 35666167
Eur Neurol. 2013;69(5):281-8
pubmed: 23445615
Parkinsonism Relat Disord. 2014 Apr;20(4):376-81
pubmed: 24508574
Neurology. 2019 May 28;92(22):e2559-e2570
pubmed: 31043471
Brain. 2010 Sep;133(9):2664-76
pubmed: 20802207
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Neurol Neurosurg Psychiatry. 1996 Jul;61(1):70-4
pubmed: 8676165
Mov Disord. 2010 Oct 30;25(14):2438-44
pubmed: 20976738
Arch Neurol. 2011 Dec;68(12):1550-6
pubmed: 21825213
Mov Disord Clin Pract. 2021 Oct 18;9(1):48-59
pubmed: 35005065
Chin Med J (Engl). 2015 Sep 20;128(18):2433-8
pubmed: 26365958
Brain. 2012 May;135(Pt 5):1463-77
pubmed: 22508959
J Neurol. 2016 May;263(5):895-905
pubmed: 26964542
Mov Disord. 2011 Nov;26(13):2327-34
pubmed: 22012750
J Neurol Neurosurg Psychiatry. 2020 Jul;91(7):687-694
pubmed: 32371534
Parkinsonism Relat Disord. 2019 Dec;69:48-54
pubmed: 31677455
Mov Disord. 2008 Apr 30;23(6):837-44
pubmed: 18307261

Auteurs

Anna Castrioto (A)

Inserm, U1216, Grenoble Alpes University Hospital Center, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.

Bettina Debû (B)

Inserm, U1216, Grenoble Alpes University Hospital Center, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.

Emilie Cousin (E)

CNRS LPNC UMR 5105, Grenoble Alpes University, Grenoble, France.
UMS IRMaGe Grenoble University Hospital Center, Grenoble Alpes University, Grenoble, France.

Pierre Pelissier (P)

Inserm, U1216, Grenoble Alpes University Hospital Center, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.

Eugénie Lhommée (E)

Inserm, U1216, Grenoble Alpes University Hospital Center, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.

Amélie Bichon (A)

Inserm, U1216, Grenoble Alpes University Hospital Center, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.

Emmanuelle Schmitt (E)

Inserm, U1216, Grenoble Alpes University Hospital Center, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.

Andrea Kistner (A)

Inserm, U1216, Grenoble Alpes University Hospital Center, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.

Sara Meoni (S)

Inserm, U1216, Grenoble Alpes University Hospital Center, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.

Eric Seigneuret (E)

Department of Neurosurgery, Grenoble Alpes University Hospital Center, Grenoble, France.

Stephan Chabardes (S)

Inserm, U1216, Grenoble Alpes University Hospital Center, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.

Paul Krack (P)

Department of Neurology, Inselspital, University Hospital Bern, Bern, Switzerland.

Elena Moro (E)

Inserm, U1216, Grenoble Alpes University Hospital Center, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.

Valérie Fraix (V)

Inserm, U1216, Grenoble Alpes University Hospital Center, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH